Issue
Alert me when new journal issues are available via or via
Masthead page ii Full-Text PDF (31 KB)
Editorial board page iii Full-Text PDF (65 KB)
Contents pages v-vi Full-Text PDF (50 KB)
Message from the Editor Michael J. Droller pages 89-90 Full Text | Full-Text PDF (46 KB)
News and Topics
Open versus robotic radical prostatectomy Herb Lepor pages 91-93 Full Text | Full-Text PDF (60 KB)
Original Articles
Prognostic factors for first recurrence in patients with retroperitoneal sarcoma Christophe Avancès, Nicolas Mottet, Aba Mahatmat, Eliette Chapuis, Isabelle Serre, Stéphane Culine pages 94-96 Abstract | Full Text | Full-Text PDF (70 KB)
Overexpression of α-defensin is associated with bladder cancer invasiveness Daniel A. Holterman, Jose I. Diaz, Peter F. Blackmore, John W. Davis, Paul F. Schellhammer, Alberto Corica, Oliver J. Semmes, Antonia Vlahou pages 97-108 Abstract | Full Text | Full-Text PDF (960 KB)
Differences in gene expression between noninvasive and invasive transitional cell carcinoma of the human bladder using complementary deoxyribonucleic acid microarray: Preliminary results Essam Elsamman, Tomoharu Fukumori, Ashraf A. Ewis, Nermin Ali, Kazuaki Kajimoto, Yasuo Shinohara, Mitsuru Ishikawa, Masayuki Takahashi, Masa-aki Nishitani, Yoshinobu Baba, Hiro-omi Kanayama pages 109-115 Abstract | Full Text | Full-Text PDF (432 KB)
Special Communication
Society of Urologic Oncology 2005 award winners Robert C. Flanigan page 116 Full Text | Full-Text PDF (44 KB)
Seminar Section Overview
Strategies for targeted tumor assessment and elimination: The physician-scientist and the blossoming of molecular medicine in urologic oncology Kenneth S. Koeneman pages 117-118 Abstract | Full Text | Full-Text PDF (56 KB)
Seminar Section Introduction
Prostate cancer stem cells, telomerase biology, epigenetic modifiers, and molecular systemic therapy for the androgen-independent lethal phenotype Kenneth S. Koeneman pages 119-121 Abstract | Full Text | Full-Text PDF (65 KB)
Seminar Articles
Telomeres and telomerase in prostatic intraepithelial neoplasia and prostate cancer biology Alan K. Meeker pages 122-130 Abstract | Full Text | Full-Text PDF (165 KB)
RETRACTED: Stem cells in prostate and prostate cancer development John S. Lam, Robert E. Reiter pages 131-140 Abstract | Full-Text PDF (335 KB)
Small molecule, oligonucleotide-based telomerase template inhibition in combination with cytolytic therapy in an in vitro androgen-independent prostate cancer model Benjamin K. Canales, Yingming Li, Melissa G. Thompson, Joseph M. Gleason, Zhi Chen, Bahaa Malaeb, David R. Corey, Brittney-Shea Herbert, Jerry W. Shay, Kenneth S. Koeneman pages 141-151 Abstract | Full Text | Full-Text PDF (417 KB)
The application of epigenetic modifiers on the treatment of prostate and bladder cancer Zhengwang Zhang, Jose Karam, Eugene Frenkel, Arthur Sagalowsky, Jer-Tsong Hsieh pages 152-160 Abstract | Full Text | Full-Text PDF (150 KB)
Development of the VCaP androgen-independent model of prostate cancer Robert D. Loberg, Lauren N. St. John, LaShon L. Day, Chris K. Neeley, Kenneth J. Pienta pages 161-168 Abstract | Full Text | Full-Text PDF (334 KB)
Editorial board page 169 Full-Text PDF (37 KB)
Increasing incidence of testicular germ cell tumors among black men in the United States: McGlynn KA, Devesa SS, Graubard BI, Castle PE, Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Department of Health and Human Services, Rockville, MD Jerome P. Richie page 170 Abstract | Full Text | Full-Text PDF (51 KB)
Incidence of late-relapse germ cell tumor and outcome to salvage chemotherapy: Ronnen EA, Kondagunta GV, Bacik J, Marion S, Bajorin DF, Sheinfeld J, Bosl GJ, Motzer RJ, Department of Medicine, Genitourinary Oncology Service, Division of Solid Tumor Oncology, Memorial Sloan-Kettering Cancer Center, New York, NY Jerome P. Richie pages 170-171 Abstract | Full Text | Full-Text PDF (57 KB)
Second cancers among 40,576 testicular cancer patients: focus on long-term survivors: Travis LB, Fossa SD, Schonfeld SJ, McMaster ML, Lynch CF, Storm H, Hall P, Holowaty E, Andersen A, Pukkala E, Andersson M, Kaijser M, Gospodarowicz M, Joensuu T, Cohen RJ, Boice JD Jr, Dores GM, Gilbert ES, Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Bethesda, MD Jerome P. Richie pages 171-172 Abstract | Full Text | Full-Text PDF (42 KB)
A phase II trial of TIP (paclitaxel, ifosfamide and cisplatin) given as second-line (post-BEP) salvage chemotherapy for patients with metastatic germ cell cancer: a medical research council trial: Mead GM, Cullen MH, Huddart R, Harper P, Rustin GJ, Cook PA, Stenning SP, Mason M, MRC Testicular Tumour Working Party, Medical Oncology Unit, Southampton General Hospital, Southampton, United Kingdom Jerome P. Richie page 172 Abstract | Full Text | Full-Text PDF (36 KB)
Retroperitoneal lymph node dissection in patients with low stage testicular cancer with embryonal carcinoma predominance and/or lymphovascular invasion: Stephenson AJ, Bosl GJ, Bajorin DF, Stasi J, Motzer RJ, Sheinfeld J, Department of Urology, Sidney Kimmel Center for Prostate and Urologic Cancers and Genitourinary Oncology Service, Memorial Sloan-Kettering Cancer Center, New York, NY Randall G. Rowland pages 172-173 Abstract | Full Text | Full-Text PDF (41 KB)
Risk of contralateral testicular cancer: a population-based study of 29,515 U.S. men: Fossa SD, Chen J, Schonfeld SJ, McGlynn KA, McMaster ML, Gail MH, Travis LB, Department of Clinical Cancer Research, The Norwegian Radium Hospital, University of Oslo, Oslo, Norway Randall G. Rowland page 173 Abstract | Full Text | Full-Text PDF (36 KB)
Modeling the cost of management options for stage I nonseminomatous germ cell tumors: a decision tree analysis: Link RE, Allaf ME, Pili R, Kavoussi LR, James Buchanan Brady Urological Institute, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Johns Hopkins Medical Institute, Johns Hopkins Hospital, Baltimore, MD Randall G. Rowland page 174 Abstract | Full Text | Full-Text PDF (37 KB)
Blood pressure and body mass index in long-term survivors of testicular cancer: Sagstuen H, Aass N, Fossa SD, Dahl O, Klepp O, Wist EA, Wilsgaard T, Bremnes RM, Department of Oncology, Institute of Clinical Medicine, University of Tromso, Tromso, Norway Randall G. Rowland pages 174-175 Abstract | Full Text | Full-Text PDF (42 KB)
Radiotherapy versus single-dose carboplatin in adjuvant treatment of stage I seminoma: a randomised trial: Oliver RT, Mason MD, Mead GM, von der Maase H, Rustin GJ, Joffe JK, de Wit R, Aass N, Graham JD, Coleman R, Kirk SJ, Stenning SP, MRC TE19 Collaborators and the EORTC 30982 Collaborators, Department of Medical Oncology, St. Bart’s and the London Hospital, London, United Kingdom Randall G. Rowland page 175 Abstract | Full Text | Full-Text PDF (36 KB)
Impact of the number of positive lymph nodes on disease-free survival in patients with pathological stage B1 nonseminomatous germ cell tumor: Beck SD, Foster RS, Bihrle R, Cheng L, Ulbright TM, Donohue JP, Departments of Urology and Pathology, Indiana University Medical Center, Indianapolis, IN Randall G. Rowland pages 175-176 Abstract | Full Text | Full-Text PDF (38 KB)
Information for Authors page CO3 Full-Text PDF (35 KB)
Copyright © 2010 Elsevier, Inc. All rights reserved | Privacy Policy | Terms & Conditions | Feedback | About Us | Help | Contact Us | The content on this site is intended for health professionals.
